We are bringing a new generation of vaccines to empower people everywhere to live healthy lives.
We are bringing a new generation of vaccines to empower people everywhere to live healthy lives.
A Better Vaccine: IVT PCV-25
Our lead candidate, Pneumococcal Conjugate Vaccine for Paediatric, leverages the Inventprise proprietary Linker Conjugation Platform to result in a longer-lasting vaccine with more coverage and a better immune response.
Proprietary Linker Conjugation Platform
Inventprise’s proprietary scalable conjugation technology based on the Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker designed to create specific, highly immunogenic, and broad-spectrum conjugate vaccines.
Proprietary Linker Conjugation Platform
Inventprise’s proprietary scalable conjugation technology based on the Hydrazied-PEG-Hydrazide (Hz-PEG-Hz) linker designed to create specific, highly immunogenic, and broad-spectrum conjugate vaccines.
READ MORE
State-of-the-Art, Highly Automated Manufacturing with Capacity to Supply Global Demand.
State-of-the-Art, Highly Automated Manufacturing with Capacity to Supply Global Demand
Recent Inventprise News
PRESS RELEASE Life Science Washington Welcomes New Board Members as the State’s Life Sciences Industry Strengthens Its Position as a Top 10 US Cluster Nine …
INVENTPRISE IN THE NEWS Inventprise President & CEO Yves Leurquin Attends 2nd Global Forum on Childhood Pneumonia Yves Leurquin shared the vision and mission of …
PRESS RELEASE Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate The 25 valent pneumococcal …